

BIOGRAPHICAL SKETCH

NAME: Masafumi Matsuda, M.D., Ph.D.
WORK PLACE: Diabetes and Metabolism Clinic,
Matsuda Clinic
3715-1 Yanai, Yanai-shi, Yamaguchi-ken ZIP 742-0021
Japan
TEL:+81-820-24-5678
FAX:+81-820-24-3388
URL <http://dm.telemed.jp>
e-mail: matsudam-ind@umin.ac.jp
matsudam@telemed.jp
POSITION: Clinical Director
BIRTH DATE: January 15, 1956
HOME ADDRESS: 3715-1 Yanai, Yanai-shi, Yamaguchi-ken ZIP 742-0021
Japan
TEL:+81-820-23-0011
Cellular:+81-90-9064-4763

Education and Academic Degree

Attached High-School of University of Hiroshima
Science 3, College of Art and Science, The University of Tokyo
Faculty of Medicine, The University of Tokyo
Bachelor of Medicine (M.D.) (March 27, 1982)
Yamaguchi University Doctor of Medical Science (Ph.D.) (July 12, 1989)

Professional Experience

Resident: University of Tokyo Hospital (Hongo, Tokyo, Japan, 6/10/82 – 1/9/83)
Resident: University of Tokyo Hospital Branch (Mezuro, Tokyo, Japan, 1/10/83 –
3/30/83)
Resident: Yamaguchi University Hospital (Ube, Yamaguchi, Japan, 4/1/83 –
8/31/83)
Resident: Shuto General Hospital (Yanai, Yamaguchi, Japan, 9/1/83 – 5/31/84)
Staff: Yamaguchi University Hospital (Ube, Yamaguchi, Japan, 6/1/84 – 5/31/87)
Assistant: Internal Medicine, Yamaguchi University (Ube, Yamaguchi, Japan,
6/1/87 – 5/31/88)
Physician: Saiki Hospital (Nagato, Yamaguchi, Japan, 6/1/88 – 3/31/89)
Staff: Yamaguchi University Hospital (Ube, Yamaguchi, Japan, 4/1/89 – 5/31/90)
Visiting Scientist: Diabetes Division, University of Texas Health Science Center at
San Antonio (UTHSCSA) (San Antonio, Texas, USA, 6/1/90 – 2/28/93)
Clinical Instructor: Diabetes Division, UTHSCSA (San Antonio, Texas, USA, 3/1/93
– 8/31/94)
Instructor: Diabetes Division, UTHSCSA (San Antonio, Texas, USA, 9/1/94 –
8/31/96)

Assistant Professor of Medicine: Diabetes Division, UTHSCSA (San Antonio, Texas, USA, 9/1/96 – 12/31/98)

Co-Director, Clinical Research Center, Texas Diabetes Institute (1996 – 1997)

Medical Research Director, Clinical Research Center, Texas Diabetes Institute (1997– 12/31/98)

Lecturer, Diabetes Division, Internal Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan (1/1/99 – 3/31/00)

Lecturer, Endocrine and Diabetes Division, Internal Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan (4/1/00 – 12/31/05)

Lecturer (part time), Kawasaki College of Allied Health Professions, Kurashiki, Okayama, Japan (6/2/00-12/31/05)

Director, Diabetes and Endocrine Department, Kameda Medical Center (1/1/06-3/31/09)

Professor, Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University (4/1/09-12/31/19)

Lecturer (part time), Department of Diabetes and Metabolic Diseases, University of Tokyo (4/1/10-3/31/15)

Visiting Professor, Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University (1/1/20-present)

Clinical Director, Matsuda Clinic (4/1/20-present)

Consultant, Shuto General Hospital (4/1/20-present)

Boards / License

Medical Examination of National Board (Japan) May 25, 1982, No.265768

Standard ECFMG Certificate (USA) 1991 No. 0-344-588-9

Board Certificate in Internal Medicine (Japan) December 20, 1991, No.69753

Board Certificate in Hematology (Japan) April 1, 1991, No.1359 (currently inactive)

Board Certificate in Diabetology (Japan) November 29, 1993, No.1505

Board Certificate in Endocrinology and Metabolism (Japan) April 1, 1994, No.1940033

Texas State Teaching Fellow Permit No. TF-93-19 (June 3, 1993 - June 3, 1994)

Texas State Faculty Temporary License No. 31226 (December 1, 1996 - 1999)

USMLE Step 1 and Step 2 passed (1997)

USMLE Step 3 passed (1998)

Certified Physician for Residency Training of Diabetology (Japan) December 5, 1999, No. 745

Assigned Physician for Residency Training of Internal Medicine (Japan) 2001

Certified Physician for Residency Training of Endocrinology (Japan) April 1, 2004, No. 3040134

Nutrition Support Team Coordinator (Japan) April 1, 2005, No. 04-168

Fellow of the Japanese Society of Internal Medicine, December 12 2005, No.9135

Professional Honors / Grants

1991 - 1993 Juvenile Diabetes Foundation Research Fellowship

- 1993 - 1994 American Diabetes Association Mentor Based Postdoctoral Fellowship
(Mentor: Ralph A. DeFronzo, M.D.)
- 1994 - 1996 Fujisawa Corp. Research Grant "Identification of Specific Proteins in
the Insulin Resistant Subjects"
- 1996 American Diabetes Association Travel Grant
- 2001-2002 Grant-in-Aid for Scientific Research (C)(2) Japan Society for the
Promotion of Science, Ministry of Education, Culture, Sports, Science,
and Technology , Japan
"Pathophysiological Analysis of Leptin Resistance in Type 2 Diabetes
Mellitus"

Professional Societies

- 1982 Member, Japanese Society of Clinical Hematology
- 1983 Member, Japan Diabetes Society
- 1983 Member, Japan Endocrine Society
- 1983 Member, Japanese Society of Hematology
- 1985 Member, Japan Association of Medical Informatics
- 1989 Member, Japanese Society of Internal Medicine
- 1990 Member, American Diabetes Association
- 1992 Life Member, International Diabetes Federation
- 1992 Member, European Association for the Study of Diabetes
- 1999 Member, Japan Atherosclerosis Society
- 1999 Member, Japanese Society of Clinical Nutrition

Councilor of Japanese Society of Internal Medicine (2016-2020)

Councilor of Japan Endocrine Society (June 14, 2000-present)

Councilor of Japan Society of Clinical Nutrition (2001-2020)

Councilor of Japan Diabetes Society (2003-2007, 2011-2015, 2019-present)

Journal Referee

- 1994 - 1996 Reviewer of *American Journal of Physiology*
- 1995 - 1997 Reviewer of *Life Science*
- 1997 – 1998, 2004, 2005, 2008, 2010
Reviewer of *Diabetes Research and Clinical Practice*
- 2000, 2003, 2004, 2010
Reviewer of *Diabetes Care*
- 2004, 2005
Reviewer of *Diabetologia*
- 2004 Reviewer of *International Journal of Experimental Diabetes Research*
- 2004 Reviewer of *Clinical Endocrinology*
- 2005 Reviewer of *EOP*
- 2006, 2007, 2010
Reviewer of *Journal of Japan Diabetes Society [Japanese]*,
- 2007, 2010
Reviewer of *Journal of Diabetes and Its Complications*
- 2007-2010 Reviewer of *Nutrition Metabolism & Cardiovascular Diseases*
- 2007, 2009 Reviewer of *Endocrine Journal*

- 2008 Reviewer of *Internal Medicine*

- 2010 Reviewer of *Endocrinology, Diabetology International, Acta Diabetologica*
 2011 Reviewer of *Endocrine Journal, Diabetes Care, Journal of Japan Diabetes Society [Japanese], Nutrition Metabolism & Cardiovascular Diseases, Acta Diabetologica, Journal of Diabetes Investigation, Acta Paediatrics, Internal Medicine, Diabetology International*
 2012 Reviewer of *Internal Medicine, Acta Diabetologica, Diabetes/Metabolism Research and Reviews, Journal of Diabetes Mellitus, Diabetes Care, Journal of Diabetes Investigation, Nutrition Metabolism & Cardiovascular Diseases, Endocrine Journal, Journal of Atherosclerosis and Thrombosis, Journal of Diabetes and Its Complications*
 2013 Reviewer of *Endocrine Journal, Journal of Atherosclerosis and Thrombosis, Diabetes Research and Clinical Practice, Journal of Diabetes Research, Diabetes Care, Nutrition Metabolism & Cardiovascular Diseases, Diabetology International, PLOS ONE, Journal of Japan Diabetes Society [Japanese], Internal Medicine*
 2014 Reviewer of *Minerva Endocrinologica, Diabetes Care, Journal of Diabetes Investigation, Diabetology International, Internal Medicine, BMJ Open Diabetes Research & Care, Acta Diabetologica, Cardiovascular Diabetology, Endocrine Journal, Nutrition Metabolism & Cardiovascular Diseases*
 2015 Reviewer of *BMJ Open Diabetes Research & Care, Acta Diabetologica, Journal of Diabetes Investigation, Internal Medicine, Minerva Endocrinologica, Endocrine Journal, Diabetes Care, Journal of Diabetes and Its Complications, Nutrition Metabolism & Cardiovascular Diseases, Journal of Diabetes Mellitus*
 2016 Reviewer of *Journal of Diabetes Mellitus, Journal of Diabetes Investigation, Endocrine Journal, Internal Medicine, Acta Diabetologica, Minerva Endocrinologica, BMJ Open Diabetes Research & Care, Nutrition Metabolism & Cardiovascular Diseases, The Journal of Clinical Endocrinology & Metabolism, Journal of Obesity*
 2017 Reviewer of *BMJ Open Diabetes Research & Care, Endocrine Journal, Minerva Endocrinologica, Journal of Diabetes Investigation, Journal of Diabetes Research, Internal Medicine*
 2018 Reviewer of *Diabetes Therapy, Minerva Endocrinologica, Phytochemistry, PLOS ONE, Current Pharmaceutical Biotechnology, Recent Patents on Food, Nutrition & Agriculture, BioMed Research International, Diabetes Care, Journal of Diabetes Investigation*
 2019 Reviewer of *BMJ Open Diabetes Research & Care, Endocrine Journal, Diabetes Therapy, Diabetology International, Acta Diabetologica, The Journal of Clinical Endocrinology & Metabolism, Internal Medicine, PLOS ONE, Journal of Diabetes Investigation, Diabetes Care, Journal of Diabetes and Its Complications, Current Diabetes Reviews*
 2020 Reviewer of *BMJ Open Diabetes Research & Care, Diabetology International, Diabetes Therapy, The Journal of Diabetes Research, Journal of Diabetes Investigation, Scientific Journal of Food Science & Nutrition, PLOS ONE, Minerva Endocrinologica, Diabetic Medicine, Obesity Research & Clinical Practice, Current Diabetes Reviews*
- 2005 Editorial Board Member of *Journal of Japan Diabetes Society*
 2007-2012 Editorial Board Member of
 Nutrition Metabolism & Cardiovascular Diseases
 2020- Associate Editor of *BMJ Open Diabetes Research & Care*

Other

- Permanent Resident of the USA (from 1996 – 2004)
 Chairman of a Sectional Meeting: Case C0048, *Medical Accident Investigation and Support Center Japan* (2018-2019)

Bibliography

1. Books / Chapters

1. Matsuda M: Manual of management of plasma glucose conc. in the clinic. Kanehara Shuppan, Tokyo Japan, pp 1-190, 2017. [Japanese]
2. Matsuda M: Manual of management of plasma glucose conc. in the hospital. Kanehara Shuppan, Tokyo Japan, pp 1-166, 2010. [Japanese]
3. Matsuda M: Why Biguanides were not used for a certain period of time. E. R. Kawamori, Fuji Medical, Osaka, Japan pp 29-36, 2005. [Japanese]
4. Matsuda M, Kaku K: Therapeutic Guide Line of Diabetes Mellitus Ed. K. Shirota and K. Node, Medical View, Tokyo, Japan pp 240-245, 2004. [Japanese]
5. Matsuda M: Self Monitor of Blood Glucose. In Kaku K (Ed) Insulin Q&A Japan Medical Publisher, Tokyo, Japan pp.67-74, 2004. [Japanese]
6. Matsuda M: Recent advances in the pathophysiology and diagnosis in Diabetology. In Yazaki Y (Ed) Progress in Molecular Diabetology – from basic to clinical science - Kanehara Shuppan, Tokyo, Japan, pp.102~108, 2002. [Japanese]
7. Matsuda M, Kaku K: Lactic Acidosis. In Hinohara S, Imura Y (Eds) Diabetes and Its Complications, Recent Lectures for Nurses, Nakayama Shoten, Tokyo, Japan pp.312~318, 2001. [Japanese]
8. Matsuda M: Comparison of Repaglinide and glibenclamide for one year. In Iwamoto Y (Ed) DATA UPDATE in Diabetes mellitus, Sentan Igakusha, Tokyo pp.146~147, 2001. [Japanese]
9. Matsuda M: Combination therapy of metformin and repaglinide. In Iwamoto Y (Ed) DATA UPDATE in Diabetes mellitus, Sentan Igakusha, Tokyo pp.144~145, 2001. [Japanese]
10. Saito M, Eto M, Okada M, Kawasaki F, Takeuchi Y, Matsuda M, Kaku K: Role of remnant-like particles (RLPs) from diabetic patients on cholesteryl ester synthesis. In Shichiri M, Chinn SH, Hotta N (Eds) Diabetes mellitus: Recent Advances from the 21st Century, Elsevier (Amsterdam, Netherlands) pp.201~204, 2000
11. Masafumi Matsuda, and Kohei Kaku: Oral Hypoglycemic Agents pp. 136-141, In Annual Review Endocrine and Metabolism 2000. [Chugai Isho], Tokyo Japan. [Japanese]
12. Masafumi Matsuda, and DeFronzo, R.A.: In vivo Measurement of Insulin Sensitivity in Human. pp. 23-65, In Draznin, B and Rizza, R (eds) Clinical Research in Diabetes and Obesity, Part I: Methods, Assessment, and Metabolic Regulation 1997 Humana Press, Totowa, NJ, USA.
13. Kohei Kaku, Matsuda, M., Kaneko, T. and Permutt, M.A.: Genetic analysis of diabetic susceptibility in inbred mouse strains. Recent advances in insulin therapy. Tai Hee Lee et al. (Ed) Springer International pp.127-130, 1990.

2. Original Papers (English)

1. Houda SM, Toshihiro U, Yuriko Y, Hiroyuki O, Reie M, Anna S, Masafumi M.: Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost *Diabetol Int.* 11(1):49-56, 2019.
2. Masako Hatano, Ikuo Inoue, Susumu Kurihara, Hiraku Onc, Masafumi Matsuda, Masafumi Kakei, Toshihiko Inukai, Yosimasa Aso, Shigehiro Katayama: Long-term efficacy and safety of add-on therapy of sitagliptin to a very small dose of glimepiride versus a small dose of glimepiride over 18 months. *J Endocrinol Metab.* 9(6):171-179, 2019.
3. Kei Nakajima, Ryoko Higuchi, Taizo Iwane, Michi Shibata, Kento Takada, Michiko Sugiyama, Masafumi Matsuda and Teiji Nakamura: High Incidence of Diabetes in People with Extremely High High-Density Lipoprotein Cholesterol: Results of the Kanagawa Investigation of Total Checkup Data from the National Database-1 (KITCHEN-1). *Journal of Clinical Medicine* 8(3):381, 2019.
4. Awata, T., Shimada, A., Maruyama, T., Oikawa, Y., Yasukawa, N., Kurihara, S., Miyashita, Y., Hatano, M., Ikegami, Y., Matsuda, M., Niwa, M., Kazama, Y., Tanaka, S., Kobayashi, T.: Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). *Diabetes Therapy* 8(5):1123-1134, 2017
5. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group.: Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial *Lancet Diabetes Endocrinol.* 5(12):951-964, 2017.
6. Akiyama, Y, Morita-Ohkubo T, Oshitani N, Ohno Y, Aso Y, Inukai T, Kakei M, Kawakami, M, Awata T, Katayama S, Matsuda M: Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study. *Diabetol Int* 7(1): 25-33, 2016.
7. Tatsumi Fuminori (Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School), Kaneto Hideaki, Hashiramoto Mitsuru, Tawaramoto Kazuhito, Obata Atsushi, Kimura Tomohiko, Shimoda Masashi, Hamamoto Sumiko, Kanda-Kimura Yukiko, Kamei Shinji, Mune Tomoatsu, Matsuda Masafumi, Kaku Kohei: Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes. *Endocrine Journal* 62(8):741-747, 2015.
8. DeFronzo RA, Matsuda M: Reduced time points to calculate the composite index *Diabetes Care* 33:e93, 2010.

9. Jani R, Molina M, Matsuda M, Balas B, Chavez A, DeFronzo RA, Abdul-Ghani M.: Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. *Diabetes Care* 31:311-5, 2008.
10. Abdul-Ghani M, Matsuda M, Jani R, Jenkinson CP, Richardson DK, Kaku K, DeFronzo RA.: The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. *Am J Physiol Endocrinol Metab.* 295:E401-6, 2008.
11. Kanda Y, Matsuda M, Tawaramoto K, Kawasaki F, Hashiramoto M, Matsuki M, Kaku K.: Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone. *Diabetes Res Clin Pract.* 81:13-8, 2008.
12. Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Ohkuma Seitaro, Kohei Kaku: Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. *Journal of Pharmacological Sciences.* 108(3):274-9, 2008. Epub 2008 Nov 6.
13. Abdul-Ghani MA, Matsuda M, DeFronzo RA.: Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects. *Diabet Med.* 25:1289-94, 2008.
14. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA.: Thiazolidinediones Improve Beta-Cell Function in Type 2 Diabetic Patients. *Am J Physiol Endocrinol Metab.* 292:E871-83, 2007.
15. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA.: Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. *Diabetes Care* 30:89-94, 2007.
16. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K.: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. *J Pharmacol Exp Ther.* 322:1-7, 2007.
17. Matsuki M, Matsuda M, Kohara K, Shimoda M, Kanda Y, Tawaramoto K, Shigetoh M, Kawasaki F, Kotani K, Kaku K.: Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. *Endocr J.* 54:571-6, 2007.
18. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K.: First phase of glucose-stimulated insulin secretion from MIN 6 cells does not always require extracellular calcium influx. *J Pharmacol Sci.* 101:293-302, 2006.
19. Saito M, Kuratsune H, Nitta H, Kawahara K, Hamano M, Matsuda M, Kaku K, Eto M.: Plasma lipid levels and nutritional intake in childhood- and adolescence-onset young type 1 diabetic patients in Japan. *abetes Res Clin Pract.* 2006 Jan 25; [Epub ahead of print]
20. Kanazawa A, Kawamura Y, Sekine A, Iida A, Tsunoda T, Kashiwagi A, Tanaka Y, Babazono T, Matsuda M, Kawai K, Iizumi T, Fujioka T, Imanishi M, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakamura Y, Maeda S.: Single nucleotide

- polymorphisms in the gene encoding Kruppel-like factor 7 are associated with type 2 diabetes. *Diabetologia*. 2005 Jun 4; [Epub ahead of print]
21. Maeda S, Tsukada S, Kanazawa A, Sekine A, Tsunoda T, Koya D, Maegawa H, Kashiwagi A, Babazono T, Matsuda M, Tanaka Y, Fujioka T, Hirose H, Eguchi T, Ohno Y, Groves CJ, Hattersley AT, Hitman GA, Walker M, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Kamatani N, McCarthy MI, Nakamura Y.: Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus. *J Hum Genet*. 2005 Jun 7; [Epub ahead of print]
 22. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D, Babazono T, Tanaka Y, Matsuda M, Kawai K, Iizumi T, Imanishi M, Shinosaki T, Yanagimoto T, Ikeda M, Omachi S, Kashiwagi A, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakajima M, Nakamura Y, Maeda S.: Genetic Variations in the Gene Encoding ELMO1 Are Associated With Susceptibility to Diabetic Nephropathy. *Diabetes*. 54:1171-8, 2005.
 23. Hara K, Ninomiya Y, Uchida M, Kawasaki F, Matsuda M, Matsuki M, Kaku K: Instruction and acceptance of patients during the introduction of the injector (OptiPen® Pro 1) from Novo FlexPen system. [*Iryo Yakugaku*] 31(8):652-658, 2005.
 24. Matsuda M, Kawasaki F, Inoue H, Kanda Y, Yamada K, Harada Y, Saito M, Eto M, Matsuki M, Kaku K: Possible contribution of adipocytokines on diabetic neuropathy. *Diabetes Res Clin Pract*. 66 Suppl 1:S121-3, 2004.
 25. Kanda Y, Yamada K, Harada Y, Kawasaki F, Saito M, Inoue H, Matsuda M, Katsuki M, Eto M, and Kaku K: Clinical Parameters for Predicting Possibility of Insulin Therapy Withdrawal in Patients with Type 2 Diabetes Mellitus *J. Jan Diab. Soc.* 47(4):271-275, 2004. [Japanese]
 26. Fumiko Kawasaki, Masafumi Matsuda, Yukiko Kanda, Hiroshi Inoue, and Kohei Kaku: Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. *Am J Physiol Endocrinol Metab*. 288:E510-518, 2005.
 27. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA.: Beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. *J Clin Endocrinol Metab*. 90:493-500, 2005.
 28. Yukiko Kanda, Kayo Yamada, Yumiko Harada, Fumiko Kawasaki, Mieko Saito, Hiroshi Inoue, Masafumi Matsuda, Michihiro Matsuki, Masaaki Etou, Kohei Kaku: Clinical Parameters for Predicting Possibility of Insulin Therapy Withdrawal in Patients with Type 2 Diabetes Mellitus. *J. Japan Diab. Soc.* 47: 271-275, 2004. [Japanese with English Abstract]
 29. Kanazawa A, Tsukada S, Sekine A, Tsunoda T, Takahashi A, Kashiwagi A, Tanaka Y, Babazono T, Matsuda M, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakamura Y, Maeda S.: Association of the Gene Encoding Wingless-Type Mammary Tumor Virus Integration-Site Family Member 5B (WNT5B) with Type 2 Diabetes. *Am J Hum Genet*. 75:832-43, 2004
 30. Saito M, Eto M, Nitta H, Kanda Y, Shigeto M, Nakayama K, Tawaramoto K, Kawasaki F, Kamei S, Kohara K, Matsuda M, Matsuki M, Kaku K.: Effect of

- apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients. *Diabetes Care*. 27:1276-80, 2004
31. M. Matsuda, F. Kawasaki, K. Yamada Y. Kanda, M. Saito, M. Eto, M. Matsuki, and K. Kaku: Impact of Adiposity and Plasma Adipocytokines on Diabetic Angiopathies in Japanese Type 2 Diabetic Subjects. *Diabetic Medicine* 21(8):881-8, 2004
 32. Hamano M, Saito M, Eto M, Suda H, Matsuda M, Matsuki M, Yamamoto S, Kaku K: Serum smyroid A (SAA), C-reactive protein and remnant-like lipoprotein particles (RLP)-cholesterol in type 2 diabetic patients with coronary heart disease. *Ann. Clin. Biochem.* 41(Pt 2):125-9, 2004
 33. Kaku K, Kawasaki F, Kanda Y, Matsuda M: Retained capacity of glucose-mediated insulin secretion in patients with type 2 diabetes mellitus inversely correlates with the duration of diabetes. *Diabetes Res Clin Pract* 64:221-3, 2004
 34. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA.: Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. *Diabetologia*. 47:31-9, 2004
 35. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, Mari A, DeFronzo RA.: Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. *Diabetologia*. 46:1211-9, 2003
 36. Ferrannini E, Gastaldelli A, Matsuda M, Miyazaki Y, Pettiti M, Glass L, DeFronzo RA.: Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. *J Clin Endocrinol Metab*. 88:3251-7, 2003
 37. Saito M, Eto M, Nisimatsu S, Kume Y, Kawasaki H, Yoneda M, Matsuda M, Matsuki M, Kaku K: Case of familial hypoalphalipoproteinemia, type 2 diabetes mellitus and markedly advanced atherosclerosis with ABCA1 gene 4 minus transcript in macrophages *Nippon Naika Gakkai Zasshi*. 91(9):2762-4, 2002. [Japanese]
 38. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E: Metabolic effects of visceral fat accumulation in type 2 diabetes. *J Clin Endocrinol Metab* 87:5098-5103 2002
 39. Matsuda M, Kawasaki F, Mikami Y, Takeuchi Y, Saito M, Eto M, Kaku K: Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin induced diabetes *Eur J Pharm* 453:141-148, 2002.
 40. Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, Del Prato S: Glucagon dose response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals *Metabolism* 51:1111-1119, 2002.
 41. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients *J Clin Endocrinol Metab* 87:2784-2791, 2002.

42. Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K: Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients *Am J Kidney Dis* 40:243-251, 2002.
43. Miyazaki Y, Matsuda M, DeFronzo RA: Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes *Diabetes Care* 25:517-523, 2002.
44. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone *Diabetes Care* 24:710-719, 2001.
45. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients *Diabetologia* 44:2210-2219, 2001.
46. Iozzo P, Pratipanawatr T, Pijl H, Vogt C, Kumar V, Pipek R, Matsuda M, Mandarino LJ, Cusi KJ, DeFronzo RA: Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis *Am J Physiol Endocrinol Metab* 280:E712-E719, 2001.
47. Matsuda M, Hiramatsu S, Teramoto F, Kawasaki F, Kaku K: Sparing of fat during basal metabolism in female diabetic patients *Proceedings of the annual meeting of Japanese society of molecular medicine* 37:26, 2000.
48. Kaku K, Matsuda M, Urae A, Irie S: Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers *Diabetes Res Clin Pract* 49:119-126, 2000.
49. Liu Y, Fox PT, Liu H-L, Mao J, Matsuda M, Gao J-H: Temporal clustering analysis for tracing the maximal fMRI response in human brain *Proc Intl Soc Mag Reson Med* 8:238 2000.
50. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA: Bromocriptine: a novel approach to the treatment of type 2 diabetes. *Diabetes Care* 23:1154-1161, 2000.
51. Insulin Sensitivity Indexes Calculated From Oral Glucose Tolerance Test Data: Response to Belfiore Matsuda M, DeFronzo RA *Diabetes Care* 23:1595-1596, 2000.
52. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp *Diabetes Care* 22:1462-1470, 1999.
53. Matsuda M, Liu Y, Mahankali S, Pu Y, Mahankali A, Wang J, DeFronzo RA, Fox PT, Gao JH: Altered hypothalamic function in response to glucose ingestion in obese humans *Diabetes* 48:1801-1806, 1999.
54. Matsuda M, Mandarino L, DeFronzo RA: Synergistic interaction of magnesium and vanadate on glucose metabolism in diabetic rats *Metabolism* 48:725-731, 1999.

55. Del Prato S, Matsuda M, Simonson DC, Groop LC, Sheehan P, Leonetti F, Bonadonna RC, DeFronzo RA: Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. *Diabetologia* 40:687-97, 1997
56. Bahl,J.J., Matsuda,M., DeFronzo,R.A., and Bressler,R.: *In vitro* and *in vivo* suppression of gluconeogenesis by inhibition of pyruvate carboxylase. *Biochemical Pharmacology* 53:67-74, 1997.
57. Kristal,B.S., Jackson,C.T., Chung,H.-Y., Matsuda,M., Nguyen,H.C., and Yu,B.P.: Defects at Center P Underlie Diabetes-Associated Mitochondrial Dysfunction: Free Radical Biology and Medicine 22:823-833, 1997.
58. Bressler,P., Bailey,S.R., Matsuda,M., DeFronzo,R.A.: Insulin Resistance and Coronary Artery Disease. *Diabetologia* 39:1345-1350, 1996.
59. Kristal,B.S., Matsuda,M., and Yu,B.P.: Abnormalities in the Mitochondrial Permeability Transition in Diabetic Rats. *Biochem.Biophys.Research Comm.* 222:519-523, 1996.
60. Giordano,M., Matsuda,M., Sanders,L., Canessa M.L., and DeFronzo,R.A.: The effects of angiotensin-converting enzyme inhibitors, Ca²⁺ channel antagonists, and β -adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. *Diabetes* 44:665-671, 1995
61. DelPrato,S., Leonetti,F, Simonson,D.C., Sheehan,P., Matsuda,M., and DeFronzo,R.A.: Effect of sustained physiologic hyperinsulinemia and hyperglycemia on insulin secretion and insulin sensitivity in man. *Diabetologia* 37:1025-1035, 1994.
62. Masafumi Matsuda: In vivo techniques for clinical studies of glucose metabolism. *Bulletin of the Yamaguchi Medical School* 41: 155-168, 1994.
63. Bonora,E., Bonadonna,R., DelPrato,S., Gulli,G., Matsuda,M., Solini,A., and DeFronzo,R.A.: In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. *Diabetes* 42:764-772,1993.
64. Masafumi Matsuda, Kaku,K., Aoki,M., Inoue,H., and Kaneko,T.: Sulfonylurea enhances insulin-induced acetyl-CoA carboxylase activity in rat adipocytes. *Horm.Met.Res.*23:209-212, 1991.
65. Matsutani,A., Kaku,K., Aoki,M., Mori,K., Matsuda,M. and Kaneko,T.: Possible mechanism of proteolysis for the extra-pancreatic action of tolbutamide. *Diabetes Res Clin Pract* 12:35-40, 1991.
66. Shinohara,K., Ayame,H., Tanaka,M., Matsuda,M., Ando,S. and Tajiri, M.: Increased production of tumor necrosis factor- α by peripheral blood mononuclear cells in the patients with aplastic anemia. *Am.J.Hematol.* 37:75-79, 1991.
67. Kenji Shinohara, Tanaka,M., Matsuda,M., Tanaka,H., Fujii,Y., Yamada,K. and Kaneko,T.: Gamma interferon production and two-color fluorescence flow cytometry analysis of peripheral blood mononuclear cells in allogenic bone marrow transplant recipients. *Acta Haematol Jpn.* 53: 76-83, 1990.
68. Shinohara,K., Ayame,H., Kodama,T. and Matsuda,M.: Study of suppression of hematopoiesis in the patients with hepatitis. *Japanese Archives of Internal Medicine* 37:159-164, 1990.

69. Hiroyuki Tanaka, Shinohara,K., Tanaka,M., Matsuda,M. and Kaneko,T: Flow cytometry analysis and gamma interferon production of peripheral blood mononuclear cells in aplastic anemia. *Jpn.Arch.Int.Med.* 36: 385-391, 1989.
70. Masafumi Matsuda and Kaneko,T.: Application of MUMPS for the management of diabetic patients on a lap-top computer. *Japan J.Med.Info.* 8: 235-244, 1988.
71. Matsuda,M., Fujii,Y., Kaneko,T., Juji,T. and Kaihara,S.: Data management system for HLA on PC-9801 (a desk top personal computer) and PC-98LT (a lap-top computer). *J. C. Med. Info.* 8: 257-258, 1988.
72. Masako Tsuchiya, Kaku,K. Matsuda,M., Kaneko,T. and Yanaihara,N: Demonstration of receptors specific for peptide N-terminal histidine and C-terminal isoleucine (PHI) using rat PHI and rat dispersed pineal cells. *Biomedical Research* 8: 45-51, 1987.
73. Shinya Fujii, Matsuda,M., Okuya,S., Yoshizaki,Y., Kora-Miura,Y. and Kaneko,T.: Fructose-6-phosphate,2-kinase activity in human erythrocytes. *Blood* 70: 1211-1213, 1987.
74. Yukari Kora-Miura, Fujii,S., Matsuda,M., Yutaka,S., Kaku,K. and Kaneko,T.: Electrophoretic determination of fructose-6-phosphate,2-kinase. *Anal.Biochem.* 170: 372-375, 1987.
75. Kohei Kaku, Fujii,S., Ando,S., Yaga,K., Inoue,M., Inoue,Y., Okubo,M., Fujii,Y., Matsutani,A., Azuno,Y., Matsuda,M., Sato,Y., Mori,K., Tanaka,H., Tanaka,M., Kaneko,T. and Ariyoshi,K.: Relationship between clinical efficiency of cefoperazone and the value of area under the time concentration curve in infectious diseases. *The Japanese Journal of Antibiotics* 40: 77-85, 1987.
76. Masafumi Matsuda, Kaku,K., Matsutani,A., Tsuchiya,M., Okuya,S. and Kaneko,T.: DG-5128 modification of the liver fructose 2,6-bisphosphate concentration suppressed by glucagon and epinephrine. *Peptide Hormones in Pancreas* 7: 229-233, 1987.
77. Masafumi Matsuda and Kaku,K.: Tissue metabolic specificity to insulin and sulfonylureas and its actions. *Journal of Japan Diabetes Society* 30:1193-1194, 1987.
78. Shinya Fujii, Matsumura,S., Yaga,K., Kaku,K., Ishida,Y., Matsuda,M., Yoshizaki,Y., Azuno,Y. and Kaneko,T.: Therapy of hypertension in the diabetic: Effectiveness of Metoprolol (Seloken). [*Shinyakuto Rinsho*] 36: 1636-1643, 1987.
79. Kohei Kaku, Matsuda,M., Matsutani,A. and Kaneko,T.: Effect of tolbutamide on fructose-6-phosphate,2-kinase and fructose-2,6-bisphosphatase in rat liver. *Biochem.Biophys.Res.Comm.* 139: 687-692, 1986.
80. Masafumi Matsuda, Kaku,K., Hatao,K. and Kaneko,T.: Tolbutamide and insulin stimulation of fructose-2,6-bisphosphate formation in hepatocytes differ. *Diabetes Research and Clinical Practice* 2: 347-335, 1986.
81. Masafumi Matsuda, Kaku,K. and Kaneko,T.: Regulation of muscle fructose 2,6-bisphosphate levels by sulfonylureas. *Endocrinol.Japon.* 33: 913-917, 1986.
82. Hiroko Sasaki, Fujii,S., Azuno,Y., Matsuda,M., Yoshizaki,Y., Yaga,K., Kaku,K. and Kaneko,T.: Clinical evaluation of treatment with intravenous tobramycin for serious infections. *Chemotherapy* 34: 271-275, 1986.

83. Kohei Kaku, Tsuchiya,M., Matsuda,M., Inoue,Y., Kaneko,T. and Yanaihara,N.: Light and agonist alter vasoactive intestinal peptide binding and intracellular accumulation of adenosine 3'5'-monophosphate in the rat pineal gland. *Endocrinology* 117: 2371-2375, 1985.
84. Katsuhiko Hatao, Kaku,K., Matsuda,M., Tsuchiya,M. and Kaneko,T.: Sulfonylurea stimulates liver fructose 2,6-bisphosphate formation in proportion to its hypoglycemic action. *Diabetes Research and Clinical Practice* 1: 49-53, 1985.
85. Shigeichi Matsumura, Tsuchiya,M., Matsuda,M., Hatao,K., Yaga,K., Kaku,K. and Kaneko,T.: The influence of glucomannan intake on the intestinal absorption of trace elements. *Yamaguchi Medical Journal* 34: 67-71, 1985.
86. Masafumi Matsuda, Inoue,M., Tajiri,M., Matsumoto,N. and Kaneko,T.: Two cases of agranulocytosis during the medication of cinepazide. *Japanese J.Clin.Hematol.* 26: 1992-1796, 1985.

4. **Review (Academic Journal including Japanese)**

1. Matsuda M: Measuring and estimating insulin resistance in clinical and research settings. *Nutrition, Metabolism & Cardiovascular Diseases* 20:79-86,2010.
2. Matsuda M: Diagnosis of insulin resistance [Hormone to Rinsho] 53(11):1159-1167, 2005 [Japanese]
3. Matsuda M: HOMA index [Seijinbyo to Seikatsu Shukanbyo] 35(8):887-890, 2005. [Japanese]
4. Matsuda M, Kaku K: Rosiglitazone [Sogo Rinsho] 54:1568-1573, 2005. [Japanese]
5. Matsuda M: How to diagnose Metabolic Syndrome *Medical Practice* 21:2005-2008, 2004. [Japanese]
6. Matsuda M: Insulin Detemir. *Practice* 21:284-288, 2004. [Japanese]
7. Matsuda M: Glucose clamp. *Diabetes Frontier* 14:304-308, 2003. [Japanese]
8. Matsuda M, Kaku K: Cutting edge of pathophysiology and therapy in Diabetes mellitus; Assessment of Insulin Resistance. *Current Therapy* 21: 27-31, 2003. [Japanese]
9. Matsuda M, Kaku K: Repaglinide (NN-623). [Nippon Rinsho] 60 Suppl 9:555-8, 2002. [Japanese]
10. Matsuda M: Ready to use EBM in Diabetes Mellitus. [Rinshoi] 28:1930-1938, 2002. [Japanese]
11. Matsuda M, Kaku K: Insulin Aspart, Its Features and Points of Therapy. *Practice* 19:153-157, 2002. [Japanese]
12. Matsuda M, Kaku K: Therapy in Diabetes Complications, Management of Microangiopathy that derange QOL. *Mebio* 19:65-69, 2002. [Japanese]
13. Matsuda M, Kaku K: Therapy of dyslipidemia. [Shinyaku to Chiryō] 51:23-25, 2001. [Japanese]
14. Matsuda M: Assessment of Insulin Resistance. *Diabetes Frontier* 11:635-645, 2000. [Japanese]

15. Matsuda M, Kaku K.: Drug Therapy [Igaku to Yakugaku] 43:194-202, 2000. [Japanese]
16. Matsuda,M, Kaku,K.: Basic and application of sulphonylurea drugs considering the mechanism of action. [Horumon to Rinsho] 47:88-94, 1999. [Japanese]
17. Kaku,K, Matsuda,M: Role of alpha-glucosidase inhibitor on the treatment of type 2 diabetes mellitus. [Naibunpi Tounyoubyou-ka] 8: 355-360, 1999. [Japanese]
18. DeFronzo,R.A., Matsuda,M., and Barrett,E.J.: Diabetic ketoacidosis: A combined metabolic-nephrologic approach to therapy. Diabetes Reviews 2:209-238, 1994
19. Masafumi Matsuda and Kaneko,T.: Antidiabetic Agents [Saishin Igaku] 45: 953-955, 1990. [Japanese]
20. Masafumi Matsuda and Kaku,K.: Extra-pancreatic action of sulfonylureas. Diabetes Frontier 1:609-614, 1990. [Japanese]
21. Masafumi Matsuda: Drug therapy, hypoglycemic reagents. [Rinshooi] 15: 424-427, 1989. [Japanese]
22. Masafumi Matsuda and Kaneko,T.: Various factors related to carbohydrate metabolism. Gastro-entero-pancreatic hormones. [Nippon Rinsho] 47: 2415-2419, 1989. [Japanese]
23. Masafumi Matsuda and Kaneko,T.: Indication of sulfonylureas - recent point of view - Journal of Clinical Science 24: 1428-1433, 1988. [Japanese]
24. Toshio Kaneko and Matsuda,M.: Mechanism of hypoglycemic action of sulfonylurea. Diabetes Journal 15:1-8, 1987. [Japanese]

Letter, Proceedings

1. 2. Liu Y, Fox PT, Liu H-L, Mao J, Matsuda M, Gao J-H : Temporal clustering analysis for tracing the maximal fMRI response in human brain. Proc Intl Soc Mag Reson Med 8:238 2000.
2. Saito M, Eto M, Okada M, Kawasaki F, Takeuchi Y, Matsuda M, Kaku K: Role of remnant-like particles (RLPs) from diabetic patients on cholesteryl ester synthesis. In Shichiri M, Chinn SH, Hotta N (Eds) Diabetes mellitus: Recent Advances for the 21st Century, Elsevier (Amsterdam, Netherlands) pp.201~204, 2000.
3. Okada M, Eto M, Saito M, Kawasaki F, Takeuchi Y, Matsuda M, Kaku K.: Responses of plasma triglyceride to fat load in type 2 diabetic patients with normal triglyceride level. In Shichiri M, Chinn SH, Hotta N (Eds) Diabetes mellitus: Recent Advances fro the 21st Century, Elsevier (Amsterdam, Netherlands), p187-190, 2000.
4. M Matsuda, F Kawasaki, H Inoue, Y Kanda, K Yamada, Y Harada, M Saito, M Eto, M Matsuki, and K Kaku: Possible Contribution Of Adipocytokines On Diabetic Neuropathy (Presented at the 12th Japan-Korea Symposium on Diabetes Mellitus on May 9, 2003 in Nagoya, Japan) Diabetes Res Clin Pract 66 (Suppl 1):S121-3, 2004.

5. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA: Reply to Comment on: Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. *Diabetologia* 47:31-39, 2004.
6. Matsuda M, Kawasaki F, Inoue H, Kanda Y, Yamada K, Harada Y, Saito M, Eto M, Matsuki M, Kaku K.: Possible contribution of adipocytokines on diabetic neuropathy. *Diabetes Res Clin Pract.* 66 Suppl 1:S121-3, 2004.
7. Kanda Y, Matsuda M, Hamamoto S, Kawasaki F, Kotani K, Matsuki M, Kaku K.: Analysis of waist circumference in Japanese subjects with type 2 diabetes mellitus: lack of propriety to define the current criteria of metabolic syndrome. *Diabetes Res Clin Pract.* 77 Suppl 1:S220-3, 2007.
8. DeFronzo RA, Matsuda M: Reduced time points to calculate the composite index *Diabetes Care* DOI:10.2337/dc10-0646, 2010.

Original Papers (Japanese)

1. 松村茂一, 土屋満佐子, 松田昌文, 畑尾克裕, 矢賀健, 加来浩平, 兼子俊男: Glucomannan の微量金属の吸収に及ぼす影響 山口医学 34:67-71, 1985.
2. 佐々木博子, 藤井新也, 東野洋一, 松田昌文, 吉崎美樹, 矢賀健, 加来浩平, 兼子俊男: 重症 感染症に対する Tobramycin 点滴静注法 - その有効性と安全性 - Chemotherapy 34:271-275, 1986.
3. 加来浩平, 藤井新也, 安藤慎太郎, 矢賀健, 井上昌光, 井上康, 大久保正士, 藤井康彦, 松谷朗, 東野洋一, 松田昌文, 佐藤穰, 森研一, 田仲弘行, 田中雅久, 兼子俊男, 有好邦夫: 内科領域各種感染症に対する Cefoperazone の臨床効果と AUC 値との相関性について The Japanese Journal of Antibiotics 40:77-85, 1987.
4. 藤井新也, 松村茂一, 矢賀健, 加来浩平, 石田陽治, 松田昌文, 吉崎美樹, 東野洋一, 兼子俊男: 糖尿病患者における高血圧治療 - メトプロロール(セロケン)の有用性と糖代謝に及ぼす影響 - 新薬と臨床 36:1636-1643, 1987.
5. 松田昌文, 兼子俊男: 糖尿病外来におけるラップトップパソコン上での MUMPS の利用. 医療情報学 8:235-244, 1988.
6. 篠原健次, 綾目秀夫, 児玉隆浩, 松田昌文: 肝炎後の造血抑制に関する臨床研究 (第一報) 内科宝函 37:159-164, 1990.
7. 川崎史子, 松田昌文, 平松智子, 広恵一美, 河原和枝, 守屋久美子, 加来浩平: 難消化性デキストリン配合茶飲料の有用性の検討 - 食後血糖上昇反応およびその他血中成分に及ぼす影響 - 健康・栄養食品研究 3:1-8, 2000.
8. 菅田有紀子, 山田和代, 原田友美子, 川崎史子, 斉藤美恵子, 井上寛, 松田昌文, 松木道裕, 衛藤雅昭, 加来浩平: 2 型糖尿病のインスリン療法におけるインスリン離脱可否の予測因子に関する検討 糖尿病 47:271-275, 2004.
9. 原景子, 二宮洋子, 内田昌宏, 川崎史子, 松田昌文, 松木道裕, 加来浩平: プレフィルド型インスリン製剤(ノボリン N 注フレックスペン®)からインスリン グラルギン製剤用ペン型注入器(オプチペンプロ®)への変更に伴う指導上の留意点および患者の自覚的病状の変化 医療薬学 31(8):652-658, 2005.
10. 吉川康弘, 栗原惣一, 松本繁子, 松田昌文, 細川直登, 小久保武: 簡易血糖測定装置における干渉物質・血液量不足の検討, および院内使用における注意点について 医療と検査機器・試薬 29(6): 573-581, 2006.
11. 濱本純子, 榊澤政広, 松木 道祐, 加来浩平, 松田昌文: バセドウ病による肺高血圧症の発症頻度と患者背景 臨床と研究 85: 1463-1466, 2008.
12. 川上知恵子, 吉川康弘, 松田昌文: 病棟血糖測定穿刺器具の運用面・安全管理面・認容面での評価 - BD ジニールンセットとナチュラルレットの比較 - PRACTICE 25:693-695, 2008.
13. 秋山義隆, 久野裕輝, 早川尚雅, 重藤誠, 榊澤政広, 岡部正, 松田昌文: 2 型糖尿病患者のオシロメトリック血圧測定による血管指標と FMD, IMT との比較 オシロメトリック血圧測定血管指標の意義 Progress in Medicine 30:2003-2007, 2010.
14. 秋山義隆, 重藤誠, 久野裕輝, 早川尚雅, 濱本純子, 中山桂, 坂本健太郎, 榊澤政広, 岡部正, 松田昌文: 2 型糖尿病患者におけるピオグリタゾンとグリニド薬の実臨床にお

ける長期併用効果, Source : Progress in Medicine(0287-3648)31 巻 11 号 Page2699-2703(2011.11)

15. 石井雅雄, 松田昌文, 和田誠基: DPP(dipeptidyl peptidase)-4 阻害薬治療下での SU 薬グリメピリド追加投与の有用性と安全性の検討 新薬と臨床 63(1): 86-93, 2014.
16. 松田彰, 川崎竜平, 油井綾子, セーボレー純子, 田淵麻衣, 込山敦子, 筒井侑希, 廣瀬朗子, 吉川由佳里, 桂奈緒美, 桜井順也, 松田昌文: 特定健診受診者における生育環境要因と生活習慣病の関連調査 出生時体重と耐糖能異常のリスク 糖尿病(0021-437X)59 巻 12 号 Page775-781(2016.12)
17. 犬飼敏彦, 麻生好正, 成瀬里香, 原健二, 末次麻里子, 土屋天文, 竹林晃三, 成宮学, 粟田卓也, 松田昌文, 加計正文, 石川三衛, 川上正舒, 片山茂裕: 埼玉県地区における 2 型糖尿病患者に対するシタグリプチン単独療法の短期および長期投与の有用性に関する検討 多施設共同試験(SUCCEED Trial 中間報告) Progress in Medicine(0287-3648)37 巻 2 号 Page245-253(2017.02)
18. 深井智子, 望月司, 松田昌文, 皆川真哉, 中野文夫, 吉川賢, 竹下玲, 河合裕直, 八木裕太, 田中入, 草間薫, 安井利一: 川越市における糖尿病に関わる歯科医科連携の試みに関して(第一報) 糖尿病連携手帳の記載項目での関連調査から 明海歯科医学(1881-4298)48 巻 1 号 Page1-7(2019.02)

Case Report (Japanese)

1. 松田昌文, 井上昌光, 田尻三昭, 松本昇, 兼子俊男: Cinepazide (Brendil) 服用中に発症した無顆粒球症の 2 例 臨床血液 26:1792-1796, 1985.
2. 斉藤美恵子, 衛藤雅昭, 西松伸一郎, 久米淑恵, 川崎史子, 米田正也, 松田昌文, 松木道裕, 加来浩平: 著明な動脈硬化症を呈した家族性低 HDL(high density lipoprotein)血症と 2 型糖尿病を合併した 1 例 日本内科学会雑誌 91:2762-2764, 2002.
3. 下田将司, 亀井信二, 濱本純子, 俵本和仁, 重藤誠, 菅田有紀子, 小原健司, 松田昌文, 松木道裕, 加来浩平: 肺高血圧症を合併したバセドウ病の 2 例 ホルモンと臨床 56:211-216, 2008.
4. 榊澤政広, 上地英司, 松田昌文, 本島新司: 胸腺腫瘍摘出後に繰り返す口腔カンジダ症を認め, 細胞性免疫低下を伴った 1 型糖尿病の症例. 糖尿病 51:1093-1098, 2008.
5. 重藤誠, 久野裕輝, 早川尚雅, 秋山義隆, 榊澤政広, 岡部正, 松田昌文: アプリンジン投与開始 1 か月後に薬剤性肝障害と同時に発症したことが疑われた 1 型糖尿病の 1 例. 糖尿病 52:35-38, 2009.

Review (Japanese)

1. 兼子俊男, 松田昌文: SU 剤の作用機序 (膵作用, 膵外作用) Diabetes Journal 15:1-8, 1987.
2. 松田昌文, 兼子俊男: インスリン分泌と作用 -新しい展望- (4) SU 剤の適応 -最近の観点- 臨床科学 24:1428-1433, 1988.
3. 松田昌文: 薬物療法 経口血糖降下剤 臨床医 15:424-427, 1989.
4. 松田昌文, 兼子俊男: 糖代謝調節系に関与する諸因子 膵・消化管ホルモン 日本臨床 47:2415-2419, 1989.

5. 松田昌文, 兼子俊男: 抗糖尿病薬 最新医学 45:953-955, 1990.
6. 松田昌文, 加来浩平: SU 剤の作用機構 -SU 剤の腭外作用- Diabetes Frontier 1:609-614, 1990.
7. 加来浩平, 松田昌文: UKPDS のインパクト - α -glucosidase inhibitor の役割 内分泌・糖尿病科 8:355-360, 1999.
8. 松田昌文, 加来浩平: 作用機序を考慮した SU 治療の基本と実際 ホルモンと臨床 47(夏期増刊号): 88-94, 1999.
9. 加来浩平, 松田昌文, 川崎史子, 竹内康雄: OHA療法 Diabetes Therapy 15:5-8, 1999.
10. 加来浩平, 松田昌文: インスリンや SU 剤治療によって体重増加をきたすメカニズム Diabetes Therapy 15:28, 1999.
11. 加来浩平, 松田昌文: インスリン治療にみられる注射部位の腫脹 Diabetes Therapy 15:29, 1999.
12. 加来浩平, 松田昌文, 斉藤美恵子, 川崎史子: OHA療法 Diabetes Therapy 16:5-8, 2000.
13. 松田昌文: インスリン抵抗性とその評価 Diabetes Frontier 11:635-645, 2000.
14. 松田昌文, 加来浩平: 糖尿病の治療 薬物療法 医学と薬学 43:194-202, 2000.
15. 加来浩平, 松田昌文, 竹内康雄, 川崎史子: OHA療法 Diabetes Therapy 17:5-8, 2000.
16. 加来浩平, 松田昌文, 小原健司, 川崎史子: OHA療法 Diabetes Therapy 18:5-8, 2000.
17. 加来浩平, 松田昌文, 川崎史子, 小原健司: OHA療法 Diabetes Therapy 19:5-8, 2000.
18. 松田昌文, 加来浩平: 高脂血症の患者指導のために 糖代謝と脂質代謝の異常 新薬と治療 51:23-25, 2001.
19. 松田昌文, 加来浩平: 糖尿病合併症の治療; QOL を障害する細小血管障害のマネジメント Mebio 19:65-69, 2002.
20. 松田昌文, 加来浩平: 超速効型インスリンの特徴と治療のポイント インスリンアスパルト プラクティス 19:153-157, 2002.
21. 松田昌文, 久米淑恵, 加来浩平: OHA療法 Diabetes Therapy 22:5-8, 2002.
22. 松田昌文: 今すぐ使える糖尿病の EBM 臨床医 28:1930-1938, 2002.
23. 松田昌文, 加来浩平: 糖尿病治療学の進歩 新規開発糖尿病治療薬の現況と今後の展望 非スルホニル尿素系インスリン分泌促進薬 レパグリニド(NN-623) 日本臨床 60 巻増刊号 9:555-558, 2002.
24. 松田昌文, 加来浩平: 「糖尿病-病態と治療の最前線-」 2型糖尿病の治療 病態の評価法と問題点 インスリン抵抗性 カレントセラピー 21:27-31, 2003.
25. 松田昌文: インスリン抵抗性の基礎と臨床 インスリン抵抗性の臨床的指標 -その実際と特徴- グルコースクランプ法 Diabetes Frontier 14:304-308, 2003.
26. 松田昌文: 【持効型インスリン製剤の登場 治療はどう展開するか】 持効型インスリンの特徴 インスリンデテミール プラクティス 21:284-288, 2004.
27. 松田昌文: 代謝症候群の診断の進め方 代謝症候群セミナー Medical Practice 21:2005-2008, 2004.

28. 松田昌文, 加来浩平: 特集 インスリン抵抗性 チアゾリジン誘導体の臨床 チアゾリジン誘導体の臨床薬理的評価 ロシグリタゾン Rosiglitazone 総合臨床 54:1568-1573, 2005.
29. 松田昌文: HOMA 指数 代謝症候群関連の検査法, 成人病と生活習慣病 35(8):887-890 2005.
30. 松田昌文: インスリン抵抗性の診断法, ホルモンと臨床 53(11):1159-1168: 2005.
31. 松田昌文: GLP-1 の肝・脂肪組織に対する作用 内分泌・糖尿病科 23(3):282-285, 2005.
32. 松田昌文: 糖尿病はどう治療するかー逆説的アプローチー 川崎医学会誌 31(4):209-213, 2005.
33. 松田昌文: 最新の糖尿病インスリン療法 糖尿病患者のインスリン分泌の特徴ーインスリン分泌不全とインスリン抵抗性 看護技術 52(11):931-933, 2006.
34. 中島弘二, 亀井信二, 川崎史子, 菅田有紀子, 小原健司, 小谷 光, 松田昌文, 加来浩平: マウス腭ラ氏島および MIN6 における発現遺伝子群の比較解析 Diabetes Frontier, 17(1): 113, 2006.
35. 重藤誠, 松田昌文: 【メタボリックシンドロームの実地診療 実地医家に不可欠の日常診療のすべて】 メタボリックシンドロームの実地診療・セミナー メタボリックシンドロームの検査・診断のポイントとコツ どうして各検査の正常上限値を判断基準としたのか Medical Practice(0910-1551)24 巻 9 号 Page1559-1560, 2007.
36. 松田昌文: 【臨床試験のエンドポイントの新しい方向性 合併症予防から原疾患の発症予防へ】 糖尿病の発症予防 臨床薬理(0388-1601)38 巻 4 号 Page179-182, 2007.
37. 松田昌文: わが国の心血管病大規模臨床試験の現状と課題 糖尿病臨床試験実施の現状と問題点、今後の展望 臨床薬理(0388-1601)38 巻 4 号 Page95S-96S, 2007.
38. 松田昌文: 【肝と糖尿病】 肝臓におけるインスリン抵抗性の評価 Diabetes Frontier(0915-6593)18 巻 5 号 Page504-508, 2007.
39. 重藤誠, 松田昌文: DDP-IV阻害薬 モダンフィジシャン 28(2):174-6, 2008.
40. 松田昌文: DREAM study 内分泌・糖尿病科 26(1):35-41, 2008.
41. 重藤誠, 松田昌文: 治療の実際 薬物療法 初診時の HbA1C が 8%台の場合 medicina 45(6):1005-8, 2008.
42. 松田昌文: 特集 血糖管理の ABC インスリン療法に強くなる 1章 基礎的確認事項 1: 血糖制御機構ー血糖を読む 1.血糖ーインスリンによる巧みな制御 2.血糖管理の目標値 / 3章 臨床応用編 3.周術期血糖管理 4.絶食を要する検査・処置時の対応 レジデント 1(4):14-20 54-59,2008.
43. 松田昌文: アメリカにおける大病院の現況 新時代の糖尿病学(4)ー病因・診断・治療研究の進歩ー第2版 日本臨床 66 巻 増刊号 9:542-547、2008.
44. 松田昌文: 【インスリン抵抗性の分子メカニズム】 個体のインスリン抵抗性とその指標(解説/特集/抄録あり) BIO Clinica(0919-8237)24(3):226-232, 2009.
45. 松田昌文:インスリン抵抗性・分泌低下の病態把握に基づく治療のすすめかた Medical Practice 26(4):569-572, 2009.
46. 松田昌文: 米国における 2 型糖尿病のインスリン分泌能と抵抗性 糖尿病診療マスター 7(3):235-239, 2009.

47. 松田昌文: 臨床講座 8 血糖管理とインスリン製剤の使い方 PharmaTribune 1:28-37, 2009.
48. 松田昌文:インクレチンのインスリン抵抗性改善作用 医学のあゆみ 231:755-758, 2009.
49. 松田昌文:インスリン分泌能力・インスリン抵抗性指標 内科 105:39-44, 2010.
50. 矢澤麻佐子, 松田昌文: インクレチン関連薬と低血糖・体重変化 Prog. Med 30:375-380,2010.
51. 松田昌文: 2型糖尿病治療薬の考え方ー長期間の血糖管理からの視点 月刊糖尿病 2:16-22,2010..
52. 松田昌文:インスリン抵抗性の指標とは 糖尿病レクチャー 1:75-79, 2010.
53. 秋山義隆, 松田昌文: 【インクレチン製剤 基礎と臨床】インクレチン関連薬のインスリン抵抗性改善作用は? インクレチン関連薬でインスリン抵抗性は改善しますか Q&A でわかる肥満と糖尿病 9 巻 4 号 Page582-583 (2010.07)
54. 松田昌文:リラグルチドの血糖降下作用と、体重への影響 プラクティス 27:352-355, 2010.
55. 松田昌文:周術期の血糖管理 内分泌・糖尿病・代謝内科 30:559-564, 2010.
56. 松田昌文:【糖尿病診療 2010】糖尿病の早期治療 病態に応じた治療方針の立て方 インスリン抵抗性に応じた治療方針日本医師会雑誌 139 巻特別 2 PageS130-S132(2010.10)
57. 松田昌文: 【2 型糖尿病の発症予防】 2 型糖尿病の疫学と病態 インスリン抵抗性と 2 型糖尿病発症・進展, ホルモンと臨床 58 巻 11 号 Page927-931(2010.11)
58. 松田昌文: GLP-1 受容体作動薬リラグルチドの臨床使用 2 型糖尿病治療の有用性の最大化に向けて, Progress in Medicine 31 巻 7 号 Page1753-1760(2011.07)
59. 押谷奈都子, 松田昌文: 【血糖降下薬療法のコツ】 肥満 2 型糖尿病患者の血糖降下薬療法, 月刊糖尿病 3 巻 6 号 Page109-114(2011.06)
60. 松田昌文: 【血糖管理と心血管病を考える】 低血糖と心血管病をみる, Vascular Medicine(1880-2478)7 巻 1 号 Page46-49(2011.04)
61. 松田昌文; 血液中インスリン濃度と C-ペプチド濃度, ドクターサロン 56 巻第 2 号 Page28-32, キョーリンメディカルサプライ株式会社 (2012/1/20)
62. 松田昌文, 秋山義隆: 注意を要するインスリン依存状態の治療 Sliding scale にかわる有効な周術期・緊急時の血糖管理, pp120-126, ブリットル糖尿病の病態と治療・管理のコツー進化する治療・広がる未来ー 別冊プラクティス 医歯薬出版 (2012/3/20)
63. 松田昌文, 加来浩平: 【急性期 このタイミングで血糖値をみる根拠】トピックス 知っておきたい! 低血糖・高血糖への対応 最新手技 Expert Nurse 28 巻 5 号: pp.113-117 (2012.04)
64. 松田昌文:【最新臨床糖尿病学 上-糖尿病学の最新動向-】糖尿病の予防・管理・治療 糖尿病薬物療法 糖尿病治療薬 薬理作用・適応・副作用など 新規糖尿病治療薬開発の現状と今後の展開 ブロモクリプチン 日本臨床 最新臨床糖尿病学(上) 70 巻増刊 3 : pp.734-739, (2012.05)
65. 松田昌文:【最新臨床糖尿病学 上-糖尿病学の最新動向-】糖尿病の検査・診断法 インスリン抵抗性検査 75gOGTT 検査、インスリン負荷試験、HOMA-IR、

- Matsuda index 日本臨床 最新臨床糖尿病学(上) 70 巻増刊 3 : pp.475-480, (2012.05)
66. 松田昌文: 【糖尿病治療薬 2012 皆が知りたい新しい治療 A to Z】 自己注射療法の新たな展開 ICU での血糖管理の極意 *Medicina* 49 巻 5 号: pp.861-863, (2012.05)
 67. 森田智子, 松田昌文: インスリン抵抗性の測定法と評価 *Modern Physician* 32(8): 939-942, 2012.
 68. 松田昌文: 糖尿病治療における低血糖問題を再考する *Diabetes Frontier* 23(3): 337-342, 2012.
 69. 松田昌文: 糖尿病診療に必要な知識 インスリン抵抗性の評価 糖尿病学の進歩 46 号 Page120-122(2012.09)
 70. 森田智子, 松田昌文: MAGE(mean amplitude of glycemc excursions) *Life Style Medicine* 7(1): 49-52, 2013.
 71. 西岡利彦, 池脇克則, 松居徹, 松田昌文, 済陽輝久: オメガ-3 脂肪酸製剤への期待 *Pharma Medica* 31(9): 115-121, 2013.
 72. 大野洋介, 内田香介, 森本二郎, 白石美絵乃, 田中聡, 大西由希子, 山崎知子, 藤田寛子, 根田保, 小野田教高, 秋山義隆, 松田昌文, 日向崇: 病棟でよく困る血糖コントロールの Q&A レジデントノート 15(6): 1091-1102, 2013.
 73. 秋山義隆, 松田昌文: BOT をめぐる debate インスリン療法の BOT はやむを得ないとき以外は選択しない 糖尿病の最新治療 4(2): 70-75, 2013.
 74. 松田昌文: 【最新 不安定な血糖値はこうしてコントロールする!】 ナース専科 34 巻 9 号 Page12-38(2014.08)
 75. 松田昌文: 【DPP-4 阻害薬登場後の糖尿病治療の変化】 GLP-1 受容体作動薬のポジショニング カレントセラピー 32 巻 4 号 Page368-372 (2014.04)
 76. 松田昌文: 【最新の糖尿病の実地日常診療 第一線の実地医家が実践すべき最新の診療の実際】 第一線の実地医家による具体的な日常診療のポイントと実際 糖尿病患者の手術における血糖管理のありかた *Medical Practice* 32 巻 1 号 Page97-100 (2015.01).
 77. 松田昌文: 【糖尿病診療でみんなが困る疑問を集めました。血糖コントロールがうまくいくコツ】 (第 3 章)入院診療の疑問 手術前の高血糖患者に対し、スライディングスケールで対処してよいのか? レジデントノート 16 巻 17 号 Page3245-3249 (2015.02).
 78. 森田智子, 松田昌文: 食事療法 エネルギー所要量 糖尿病治療 通説への挑戦—進化する科学知識は既存の糖尿病治療学に何を伝えたいのか 内科 Vol 115 No.4: 559-562, 2015.
 79. 松田昌文: 【インスリン抵抗性~メカニズムに基づく新しい治療法の探求~】 ヒトでのインスリン抵抗性の評価方法(SGLT2 阻害薬使用時の注意) *Diabetes Frontier*(0915-6593)26 巻 3 号 Page298-301(2015.06)
 80. 松田昌文: 【SGLT2 阻害薬の新時代~機序から臨床まで】 SGLT2 阻害が病態生理におよぼす作用 月刊糖尿病 7 巻 7 号 Page28-32(2015.07)
 81. 松田昌文: 【SGLT2 阻害薬を再評価する-明らかにしてきた効果と副作用-】 臨床試験や実臨床からわかってきた SGLT2 阻害薬の効果 明らかにしてきた、新し

い作用やメカニズム(グルカゴン上昇作用など) *Progress in Medicine*(0287-3648)36 巻 2 号 Page201-203(2016.02)

82. 松田昌文: 【SGLT2 阻害薬の適正使用を考える】 SGLT2 阻害薬の作用機序からみた代謝改善作用 *Modern Physician*(0913-7963)36 巻 2 号 Page101-104(2016.02)
83. 松田昌文: 【新時代の臨床糖尿病学(上)-より良い血糖管理をめざして-】 糖尿病の疾患概念・成因・病型分類・臨床的特徴・治療法 2 型糖尿病 2 型糖尿病の疾患概念、成因、病型分類、臨床的特徴 *日本臨床*(0047-1852)74 巻増刊 1 新時代の臨床糖尿病学(上) Page314-317(2016.02)
84. 大竹啓之, 松田昌文: 【糖尿病診療における心血管合併症の診かた up to date】 糖尿病患者における周術期心機能評価とマネジメント 糖尿病内科医の立場から 月刊糖尿病 8 巻 7 号 Page73-81(2016.07)
85. 松田昌文: 【DPP-4 阻害薬を極める～有効性と安全性を踏まえた適正使用に向けて～】 DPP-4 阻害薬と GLP-1 受容体作動薬の適切な使い分け 月刊糖尿病 8 巻 12 号 Page64-69(2016.12)
86. 秋山義隆, 森田智子, 松田昌文: 【肥満糖尿病克服への新たな挑戦】 肥満症治療薬の現状と問題点 *糖尿病*(0021-437X)59 巻 11 号 Page734-735(2016.11)
87. 松田昌文: 【糖尿病-健康長寿を実現する糖尿病の实地診療-】 セミナー 糖尿病診療のポイントの整理とその活用 *Precision medicine*(精密医療)に向けた糖尿病患者の病態把握とリスク予測に基づく实地診療 病期・合併症・重症度に基づいた治療戦略 *Medical Practice*(0910-1551)34 巻 9 号 Page1445-1447(2017.09)
88. 清水雅之, 坂行正, 黒澤万里子, 赤岩稔之, 松田昌文, 片山茂裕: 【新しい technology を活用した糖尿病診療の進歩】 ビッグデータを活用した埼玉県糖尿病重症化予防対策 *内分泌・糖尿病・代謝内科*(1884-2917)46 巻 2 号 Page80-86(2018.02)
89. 松田昌文: 【糖尿病 Q&A】 日本人 2 型糖尿病治療薬の第一選択薬は何を用いるべきか? 成人病と生活習慣病(1347-0418)48 巻 4 号 Page422-425(2018.04)
90. 松田昌文: 教育講座 一般臨床内科医として知っておくべきこと ー糖尿病診療においてー *埼玉県内科医会誌* 8 号, 2019